INTRODUCTION
Myotonic dystrophy is the commonest inherited neuromuscular disease as well as the one most varied in its clinical expression.' The myotonic dystrophy gene has recently been localised to the q 13.3 region on the long arm of chromosome 19 where there are increased numbers of cytidine-thymidine-guanidine trinucleotide repeats.2 This has enabled the diagnosis to be made on DNA extracted from peripheral blood.
Before the availability of a blood test there were numerous clinical evaluations to determine the sensitivity and specificity of various symptoms, signs, and investigations in myotonic dystrophy. These have become no less relevant now since not everyone with weakness or cataract is likely to have a gene test without some preliminary screening. Furthermore, with the existence of a gene test, there is now a "gold-standard" against which other measures can be judged. We were impressed that the frequency of muscle weakness on careful neuromuscular examination of patients with myotonic dystrophy was higher than that reported in the literature. We carried out the following study to were stained with haematoxylin and eosin, Gomori's trichrome, acid phosphatase, NADH-tetrazolium reductase and ATP-ase pre-incubated at pH 9.4, 4.6, and 4.3.
RESULTS
The frequency of weakness in each muscle group is shown in figure 1 and that of the remaining symptoms, signs, and investigations in figure 2 . Face, neck flexors, and arm external rotators were universally weak whereas knee flexion and neck extension were rarely involved. Myotonia was by definition present but was more reliably obtained by percussion than by handgrip. Cataract was the commonest somatic feature but was much less prevalent than weakness and myotonia. 
